GEN and Sulfateq BV Announce Positive Phase 1 Trial Data on Investigational Drug SUL-238 for Alzheimer's and Other Neurodegenerative Diseases
ANKARA, TR / ACCESS Newswire / July 28, 2025 / GEN Pharmaceuticals (GENIL.IS), Türkiye's leading specialty pharmaceutical company, announced positive results from its Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics (PK) of first-in-class and novel orally administered mitochondria-directed drug candidate SUL-238 in healthy elderly volunteers. The findings were presented at the Alzheimer's Association International Conference 2025 (AAIC ®) in Toronto.
This single oral ascending dose (SAD) Phase 1, first-in-human, randomized, double-blind, placebo-controlled study was conducted in three parts, involving a total of 53 healthy elderly adults. Part 1 included 6 cohorts (50, 100, 250, 500, 1000, and 2000 mg orally, n=23). In Part 2, the PK of a single 1000 mg oral dose was investigated in 10 healthy elderly adults. In Part 2B, the food effect was assessed using a randomized, single oral 2000 mg dose, two-treatment, two-period, crossover design (n=20).
The trial results showed that single oral doses of 50-2000 mg of SUL-238 were safe and well-tolerated, while demonstrating a favourable PK profile and high cerebrospinal fluid (CSF) penetration. These findings make SUL-238 a promising candidate for further clinical development in neurodegenerative diseases, including Alzheimer's disease.
No adverse effects (AEs) limited dose escalation, AE rates were comparable between SUL-238 and placebo, and all AEs were mild or moderate. The mean terminal elimination half-life was 0.86-3.80 hours, and the time to maximum plasma concentration was 0.50-1.39 hours. Under fed conditions, maximum plasma concentration (C max) and area under the plasma concentration-time curve (AUC 0-∞) decreased by 50% and 60%, respectively. CSF-to-plasma percentages at 2 and 8 hours post-dose were 21.1% (±6.6%) and 74.2% (±46.0%).
Abidin Gülmüş, Chairman of GEN, stated:
'We are very encouraged by these promising first-in-human results, marking an important step forward in our mission to address the underlying biology of Alzheimer's disease.'
Nadir Ulu, MD, PhD, Vice President of R&D at GEN, added:
'With its excellent safety and PK profile in this Phase 1 trial, combined with robust preclinical data, SUL-238 represents a strong candidate for further clinical development to meet the critical unmet needs in neurodegenerative diseases, including Alzheimer's disease.'
About SUL-238
SUL-238 is a novel, first-in-class, hibernation-derived small molecule that targets mitochondria, the cell's 'powerhouse.' It supports mitochondrial bioenergetics via complex I/IV activation and has improved mitochondrial function in rodent models of neurodegenerative, cardiovascular, and renal diseases, as well as aging. SUL-238 crosses the blood-brain barrier and has undergone extensive safety evaluation in preclinical and Phase 1 studies. GEN licenses SUL-238 from Sulfateq BV for neurodegenerative disease applications.
About GEN:
Founded in 1998, GEN is Türkiye's leading specialty pharmaceutical company, focused on developing innovative therapies across multiple therapeutic areas. GEN manufactures high-quality, competitive products at its GMP-certified facility and pursues original drug development through two dedicated R&D centers and investments.
About Sulfateq:
Sulfateq B.V. is an early-stage Dutch biotech company that fosters strategic collaborations with academic and industrial research centers to accelerate the development of innovative new medicines. It has developed a novel class of small molecules, the SUL-compounds, that maintain mitochondrial health.
Contact Information
Bulutay Güneş
Sr. Head of Corporate Brand
b.gunes@genilac.com
Ali Ketencioğlu
Investor Relations Manager
a.ketencioglu@genilac.com
Kees van der Graaf
Sulfateq CEO
View the original press release on ACCESS Newswire
The post GEN and Sulfateq BV Announce Positive Phase 1 Trial Data on Investigational Drug SUL-238 for Alzheimer's and Other Neurodegenerative Diseases appeared first on DA80 Hub.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
Alzheimer's researchers say targeting brain sugar could help protect against dementia
The brain has a hidden "sugar code" that could lead to better treatments for neurological diseases like Alzheimer's, according to new research. A study recently published in the journal Nature Metabolism found that breaking down glycogen (stored glucose) in the brain could reduce the buildup of toxic proteins linked to the common dementia. This was one of the first studies to show that glycogen may actively influence brain health and disease, according to lead author Dr. Pankaj Kapahi, a professor at the Buck Institute for Research on Aging in California. Two Cancer Drugs Show Promise In Reversing Alzheimer's Devastating Effects "The study began with fruit flies (Drosophila) that were genetically modified to mimic tauopathy, a condition where a protein called tau builds up in the brain, similar to what happens in Alzheimer's disease," Kapahi told Fox News Digital. The flies used in the study were found to have brain damage and shortened lifespans, according to the researcher. Read On The Fox News App To ensure that the results could translate to humans, the research team also studied nerve cells made in the lab from human patient cells carrying tau mutations, as well as postmortem brain samples from people who had Alzheimer's or related conditions, according to a press release. In both the fly and human models, the researchers found increased levels of glycogen (stored glucose) in the brain, as well as signs that glycogen breakdown was impaired, Kapahi told Fox News Digital. This was a surprising discovery, as researchers previously thought glycogen was mainly stored in the muscles and liver. Alzheimer's Risk Could Rise With Specific Sleep Pattern, Experts Warn They also found that the excess glycogen contributed to disease. The tau proteins in the scientists' models interacted with glycogen, blocking it from breaking down, and the nerves lost their ability to ward off cell damage. However, the researchers found they could decrease damage to the fruit flies and human nerves by boosting an enzyme called glycogen phosphorylase (GlyP), which breaks down glycogen. The nerve cells used the glycogen to fight against cell damage, suggesting that the enzymes responsible for breaking down sugar could be promising targets for future therapies. The researchers were also curious whether a restricted diet could improve the flies' brain health. When they reduced the amount of protein in the insects' diet, the flies indeed lived longer and their brain health improved. "We then discovered this improvement was linked to an increase in the breakdown of glycogen," Kapahi said. This led to the study's main finding — that breaking down glycogen in neurons can protect the brain from damage caused by tau buildup. Eating These Common Foods Could Reduce Alzheimer's Risk, Experts Say The scientists also developed a drug using a special molecule called 8-Br-cAMP that replicated similar effects of dietary restriction, the press release noted. The authors clarified that they are not recommending low-protein diets just yet — but said this research could pave the way for dietary or drug-based strategies to help slow Alzheimer's and related diseases. Dr. Michael Okun, a Florida neurologist and medical advisor to the Parkinson's Foundation, was not involved in the study but commented on the significance of the findings. "Instead of funneling sugar into energy-burning processes, the broken-down glycogen seemed to be routed into an antioxidant-producing pathway," Okun, who is also author of "The Parkinson's Plan," told Fox News Digital. "The next step in the process may be mopping up potentially damaging free radicals roaming our brains," he said. Okun also confirmed that dietary restrictions activated a protective brain pathway and boosted the breakdown of brain sugar. "It ultimately reduced damage from the Alzheimer's-related tau protein," he said. The study — which was supported by the National Institutes of Health, as well as the American Federation of Aging Research and other sources — did have some limitations, the experts acknowledged. Click Here To Sign Up For Our Health Newsletter The researchers did not clarify whether breaking down brain glycogen could stop human brain cells from dying, Okun noted. "We don't yet know why glycogen builds up in disease, or whether it's a cause or a result of tau pathology — though our data suggest it may amplify disease progression," Kapahi added. The research was also conducted only on fly and human cell models and has not yet been tested on living humans. "We still don't know if targeting glycogen breakdown will work in human patients — and most importantly, whether it will be a safe approach," Okun said. Alzheimer's disease, the most common form of dementia in the U.S., affects more than seven million people in the U.S., according to the Alzheimer's Association. For more Health articles, visit The neurological disorder affects memory, thinking and behavior. There is no cure for the disease, but some medications can temporarily slow progression and improve quality of article source: Alzheimer's researchers say targeting brain sugar could help protect against dementia Solve the daily Crossword
Miami Herald
9 hours ago
- Miami Herald
General Atomics Electromagnetic Systems Highlights Its Missile Defense Portfolio at the 2025 Space and Missile Defense Symposium
HUNTSVILLE, AL / ACCESS Newswire / August 4, 2025 / General Atomics Electromagnetic Systems (GA-EMS) returns to the Space and Missile Defense Symposium to highlight its missile defense solutions supporting Golden Dome, a layered missile defense architecture designed to protect the nation from a range of advanced missile threats including hypersonic, ballistic and cruise missiles, as well as other airborne threats. GA-EMS will showcase the designs for their Bullseye™ missile and Long-Range Maneuvering Projectile (LRMP), with a 1:1 scale model and 1:2 scale model in their booth. The company has accelerated integration and testing of its missile defense technologies to demonstrate advanced capabilities and move rapidly toward field deployment. "Our LRMP aligns with dynamic defense requirements for improved long-range precision strikes and minimizes operational uncertainty by integrating into existing artillery systems," said Scott Forney, president of GA-EMS. "The next phase of full-system testing will validate the projectile's performance across complex scenarios and ensure seamless integration with missile defense frameworks." Bullseye is a Technology Readiness Level (TRL) 8 missile system that shares 80% of its components with combat-proven TRL 9 missile systems, fully validated through successful real-world operations. Attendees visiting Booth #531 will engage directly with GA-EMS experts to explore system designs and planned field-testing initiatives for both LRMP and Bullseye. GA-EMS will also feature its portfolio of laser weapon systems, hypersonics and sensor payloads for missile defense and tracking-offering greater flexibility and capability to support both offensive and defensive missions. About General Atomics Electromagnetic Systems General Atomics Electromagnetic Systems (GA-EMS) develops innovative technologies to create breakthrough solutions supporting operational environments from undersea to space. From electromagnetic, power generation and energy storage systems and space systems and satellites, to hypersonic, missile defense, and laser weapon systems, GA-EMS offers an expanding portfolio of capabilities for defense, government, and national security customers. GA-EMS also provides commercial products and services targeting hazardous waste remediation, oil and gas, and nuclear energy industries. For further information, visit Contact Information General Atomics Electromagnetic Systems Media Relations Media Relationsems-mediarelations@ SOURCE: General Atomics Electromagnetic Systems press release
Miami Herald
10 hours ago
- Miami Herald
Traveler Care Launches Global Medical Dispatch Platform to Help Travel Insurance Companies Cut ER Claims by 80%
NEW YORK CITY, NY / ACCESS Newswire / August 4, 2025 / Traveler Care, a breakthrough medical dispatch platform that brings urgent care directly to travelers in hotels, Airbnbs, and vacation rentals, has officially launched worldwide - offering travel insurance companies a high-impact solution to reduce avoidable emergency room and hospital claims. A Concierge Alternative to the Emergency Room Traveler Care connects travel insurers and their policyholders to a network of licensed, on-call providers who visit travelers in their accommodations - typically within 60-90 minutes. Conditions such as flu, food poisoning, dehydration, allergic reactions, UTIs, sprains, and wound care are treated on-site, eliminating the need for an ER visit. "In most cases, travelers just need a doctor - not a hospital admission," said Eli Ofel, founder of Traveler Care. "We've built a scalable, insurer-ready solution that saves money and delivers a far better traveler experience." Reduce Claims by $10,000+ Per Visit On average, a non-emergency ER visit costs travel insurers $13,000 to $17,000. Traveler Care treats the same conditions in-room for $1,700 to $3,000 - including diagnostics like mobile X-ray, ultrasound, IV therapy, and wound treatment. Pilot results have shown:- 83% reduction in ER claim volume- $10,000+ savings per case avoided- Higher satisfaction scores among travelers Built for Travel Insurance Partners Traveler Care is fully designed for insurance integration - with white-label and API options available for TPAs, underwriters, and global assistance networks. Platform features:- Nationwide U.S. coverage (with international expansion underway)- A robust dispatch network, for example companies like Leaa Health, Sickday, Heal, DocGo and more, any location that the travel insurance is experiencing high volume travel care will create a solution for that particular location within 60 days.- HIPAA-compliant documentation + one-click claims integration- Supports care delivery to hotels, Airbnbs, resorts, and serviced apartments Now Onboarding Insurance Companies Worldwide "We believe travel insurance companies shouldn't just pay for care - they should deliver it smarter," said Ofel. "With Traveler Care, you lower claims without compromising care." Insurance providers, TPAs, and global assistance companies are invited to partner and deploy in-room urgent care as part of their medical benefit stack. Contact To schedule a private demo or receive our ROI case study:Visit partners@ +1 (347) 733-0563 About Eli Ofel Eli Ofel is a serial entrepreneur and visionary behind multiple AI- and tech-powered platforms in healthcare, finance, and transportation. He is the founder and CEO of Traveler Care, Leaa Health, and With over 20 years of experience in healthcare operations, insurance workflows, and mobile logistics, Ofel brings a proven ability to bridge patient needs with scalable platform solutions - saving time, money, and lives. SOURCE: Traveler care press release
